Mobile

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cel...

Update Il y a 4 ans
Reference: EUCTR2016-000706-12

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated and advanced non-clear cell RCC.

Inclusion criteria

  • The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated and advanced non-clear cell RCC

Links